An early cellular injury marker and a later functional outcome should not be treated as the same result.
The experiment exposed neonatal mice to sedative-equivalent regimens including midazolam, propofol or JM-1232. Early apoptosis-related markers differed between agents. Later behavioral testing found deficits in some midazolam or propofol groups that were not detected with the experimental comparator.
Mouse developmental stages and injected regimens do not map directly onto a child’s procedural exposure. No detectable deficit on selected tests is not proof of universal safety. Equating sedative effects also does not guarantee equal exposure or every physiological effect.
For discussing developmental risk, preserve timing, species and endpoint. Do not diagnose human injury from an animal comparison or use a favorable alternative result to dismiss clinical uncertainty. Early molecular observations and adult behavior each require their own interpretation before proposing a causal link.
Source: Publication PMC8213711. Applications to expert review are interpretive analysis.
Related reading: Deer-Mouse Lorazepam Experiment Highlights the Difficulty of Labeling Repetitive Behavior as Anxiety.